OKYO

OKYO PHARMA LTD

• TipRanks·3d ago

  OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain

• TipRanks·04/29 11:53

  OKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in Denver

• Benzinga·04/14 21:05

  12 Health Care Stocks Moving In Tuesday's After-Market Session

• TipRanks·04/13 11:37

  Piper Sandler Reaffirms Their Buy Rating on OKYO Pharma Limited Sponsored ADR (OKYO)

• Benzinga·04/08 12:05

  9 Health Care Stocks Moving In Wednesday's Pre-Market Session

• TipRanks·04/07 11:33

  OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting

• Seeking Alpha·04/03 12:20

  Most and least shorted healthcare stocks with up to $2B market cap in March

• TipRanks·03/19 16:27

  OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial

• Benzinga·03/19 16:02

  OKYO Pharma's Panetta Partners Buys 10,119 Shares At An Average Price Of $1.59, Raising Executive Chairman Gabriele Cerrone's Total Holdings To 10,526,416 Shares

• TipRanks·03/19 14:28

  OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3

• TipRanks·03/19 14:15

  Okyo Pharma director John Brancaccio acquires 5,000 shares

• Benzinga·03/19 14:06

  OKYO Pharma Director John Brancaccio Buys 5,000 Shares At An Average Price Of $1.61, Raising Total Holdings to 31,201

• TipRanks·03/19 11:48

  OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress

• TipRanks·03/19 11:37

  Okyo Pharma CDO, director acquire shares

• Benzinga·03/19 11:13

  OKYO Pharma Executive Buys More Shares, Signals Confidence